Phase 4 Type 2 Diabetes Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Type 2 diabetes and whose HbA1c blood sugar level (a measure of average blood sugar over roughly 3 months) is between 7.0% and 10.5% at the screening appointment
- People aged between 20 and 80 years old, of any gender
- People who have been taking Metformin (at a dose of at least 500mg), with or without a blood sugar-lowering medicine from the DPP-4 inhibitor group (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, or Evogliptin), for at least the past 3 months
- People with a Body Mass Index (BMI, a measure calculated from height and weight) of 23 or above
- People whose kidneys are functioning at a level measured as an eGFR of at least 60 ml/min/1.73m² (a standard test of kidney filtering ability)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have Type 1 diabetes, gestational diabetes (diabetes during pregnancy), or diabetes caused by another underlying condition
- People who have had a serious heart or cardiovascular event in the 3 months before the screening visit
- People who are pregnant or breastfeeding, or who are not using contraception
- People who have chronic Hepatitis B (unless they are a healthy carrier with no active disease) or Hepatitis C, or who have liver disease shown by certain liver enzyme levels being more than 3 times higher than the normal upper limit
- People who have heart failure or a history of heart failure
- People who have been diagnosed with cancer in the past 5 years (though people who have been fully treated for certain skin cancers or thyroid cancer may still be considered — confirm with trial site)
- People who have taken part in another clinical trial within the past 30 days
- People with alcohol addiction
- People for whom the study medications Enavogliflozin or Pioglitazone are considered medically unsuitable or contraindicated
- People who are currently taking other diabetes medications (including insulin or other blood sugar-lowering tablets) or other experimental drugs
- People considered unsuitable for the trial based on the medical team's assessment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Soo Lim, M.D. Ph.D., Seoul National University Bundang Hospital
Phone: +82317877035
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes of HbA1c from the baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.